Celgene (CELG) Release: Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients With Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes
4/26/2013 10:17:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for REVLIMID® for the treatment of patients with transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Help employers find you! Check out all the jobs and post your resume.
comments powered by